Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS G12C–mutant NSCLC (n=48) across all PD-L1...
Hence then, the article about d3 bio presents first line data for elisrasib d3s 001 at asco 2026 next generation kras g12c inhibitor shows landmark efficacy in untreated nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC )
Also on site :
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
- Andrew Scott & George MacKay Lead Voice Cast Of Russell Tovey’s Debut Novel ‘Starlings’, Which Is Being Published By Audible
- Global Waste-derived Pyrolysis Oil Market Report 2026 .. Asia Pacific Leads Demand While Shell, BASF and Agilyx Compete in Circular Polymer Feedstock